Cover Image
市場調查報告書

灰指甲(甲癬):開發平台分析

Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192747
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
灰指甲(甲癬):開發平台分析 Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 81 Pages
簡介

灰指甲為慢性的真菌性感染疾病之一,由於癬菌(皮膚絲狀真菌)傳染指甲而發病。主要的前兆、症狀為,指甲變厚難剪,指甲變脆,指甲的顏色褪色,普通動到時手指、腳尖疼痛等。主要的治療方法有抗真菌藥物的藥物治療和外科手術等。

本報告提供全球各國的灰指甲(甲癬)治療用的開發中產品的開發情形相關分析、產品開發、上市的最新趨勢,及臨床實驗的各階段處於的產品的一覽、主要企業簡介、主要藥物概要、最新的產業趨勢等資訊、為您概述為以下內容。

目錄

簡介

  • 分析範圍

灰指甲(甲癬)概要

治療藥的開發

  • 灰指甲開發中產品:概要
  • 灰指甲開發中產品:比較分析

在各企業開發中的灰指甲治療藥

在大學/研究機關研究中的灰指甲治療藥

開發中產品的概要

  • 臨床階段的產品
  • 初期階段的產品
  • 不明確階段的產品

灰指甲治療藥:開發中的產品的一覽(各企業)

灰指甲治療藥:研究中的產品的一覽(各大學/研究機關)

開發灰指甲治療藥的企業

  • Anacor Pharmaceuticals, Inc.
  • Eisai
  • Helix BioMedix, Inc.
  • Hexima Limited
  • Meiji Seika Pharma
  • Moberg Pharma AB
  • NAL Pharmaceuticals Ltd.
  • Nihon Nohyaku Co., Ltd.
  • Novabiotics Limited
  • Nuvo Research Inc.
  • Viamet Pharmaceuticals, Inc.

灰指甲:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • AN-2718
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • E-1224
  • ELS-160
  • HB-1275
  • HXP-124
  • rurikonazoru
  • ME-1111
  • NAL-3216
  • NP-213
  • terbinafine
  • terbinafine
  • VT-1161

灰指甲治療藥:開發中產品的最新趨勢

灰指甲治療藥:開發暫停的產品

灰指甲治療藥:開發中止的產品

灰指甲相關產品的開發的里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8285IDB

Summary

Global Markets Direct's, 'Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2016', provides an overview of the Onychomycosis (Tinea Unguium) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium)
  • The report reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Onychomycosis (Tinea Unguium) therapeutics and enlists all their major and minor projects
  • The report assesses Onychomycosis (Tinea Unguium) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Onychomycosis (Tinea Unguium) Overview
  • Therapeutics Development
    • Pipeline Products for Onychomycosis (Tinea Unguium) - Overview
    • Pipeline Products for Onychomycosis (Tinea Unguium) - Comparative Analysis
  • Onychomycosis (Tinea Unguium) - Therapeutics under Development by Companies
  • Onychomycosis (Tinea Unguium) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Onychomycosis (Tinea Unguium) - Products under Development by Companies
  • Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development
    • Almirall, S.A.
    • Anacor Pharmaceuticals, Inc.
    • Arno Therapeutics, Inc.
    • Blueberry Therapeutics Ltd
    • Crescita Therapeutics Inc.
    • Eisai Co., Ltd.
    • Helix BioMedix, Inc.
    • Hexima Limited
    • Meiji Seika Pharma Co., Ltd.
    • Moberg Pharma AB
    • NAL Pharmaceuticals Ltd.
    • Nihon Nohyaku Co., Ltd.
    • Novabiotics Limited
    • Novan, Inc.
    • Viamet Pharmaceuticals, Inc.
  • Onychomycosis (Tinea Unguium) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AN-2718 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BB-0305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Onychomycosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ELS-160 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fosravuconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-1275 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HXP-124 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • luliconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ME-1111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAL-3216 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-213 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-208 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • terbinafine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • terbinafine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • terbinafine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VT-1161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Onychomycosis (Tinea Unguium) - Dormant Projects
  • Onychomycosis (Tinea Unguium) - Discontinued Products
  • Onychomycosis (Tinea Unguium) - Product Development Milestones
    • Featured News & Press Releases
      • May 18, 2016: Moberg Pharma Announces Multiple Patent Approvals for MOB-015
      • Mar 02, 2016: Viamet Reports Positive Results from Interim Analysis of RENOVATE Phase 2b Trial of VT-1161 in Onychomycosis
      • Jan 21, 2016: Moberg Pharma is contemplating a potential bond issue, updates financial targets and provides update on MOB-015
      • Jan 07, 2016: Viamet to Present at the 3rd Annual Dermatology Summit
      • Aug 11, 2015: Nuvo Research Announces Grant of United States Patent for Topical Onychomycosis Formulation
      • Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting
      • Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical Treatment of Onychomycosis (Nail Fungus)
      • Mar 13, 2015: MOB-015 Data To Be Presented At The 73rd Annual Meeting Of The American Academy Of Dermatology
      • Mar 10, 2015: Viamet Announces Initiation of RENOVATE Phase 2b Study of Oral VT-1161 in Onychomycosis
      • Feb 11, 2015: Moberg Pharma Announces Issue of U.S. Patent Related to MOB-015 for the Treatment of Onychomycosis
      • Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis
      • Sep 10, 2014: Data for Viamet's VT-1161 Presented at ICAAC 2014
      • Dec 13, 2013: Moberg Pharma reports positive interim results in phase II clinical study of MOB-015
      • May 27, 2013: Moberg Pharma Completes Enrollment In Phase II Clinical Trial Of MOB-015
      • Nov 07, 2012: Moberg Derma Initiates Phase II Trial With MOB-015 For Treatment Of Onychomycosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2016
  • Number of Products under Development for Onychomycosis (Tinea Unguium) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Onychomycosis (Tinea Unguium) - Pipeline by Almirall, S.A., H2 2016
  • Onychomycosis (Tinea Unguium) - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016
  • Onychomycosis (Tinea Unguium) - Pipeline by Arno Therapeutics, Inc., H2 2016
  • Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, H2 2016
  • Onychomycosis (Tinea Unguium) - Pipeline by Crescita Therapeutics Inc., H2 2016
  • Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co., Ltd., H2 2016
  • Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix, Inc., H2 2016
  • Onychomycosis (Tinea Unguium) - Pipeline by Hexima Limited, H2 2016
  • Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2016
  • Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H2 2016
  • Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd., H2 2016
  • Onychomycosis (Tinea Unguium) - Pipeline by Nihon Nohyaku Co., Ltd., H2 2016
  • Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Limited, H2 2016
  • Onychomycosis (Tinea Unguium) - Pipeline by Novan, Inc., H2 2016
  • Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Onychomycosis (Tinea Unguium) - Dormant Projects, H2 2016
  • Onychomycosis (Tinea Unguium) - Dormant Projects (Contd..1), H2 2016
  • Onychomycosis (Tinea Unguium) - Dormant Projects (Contd..2), H2 2016
  • Onychomycosis (Tinea Unguium) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2016
  • Number of Products under Development for Onychomycosis (Tinea Unguium) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top